KZIA

Investor Moves

Name	Value	Action	Change	Price	Current Price
Steven CohenPoint72 $1.5M200k shares AddQ1 2026 $110k $7.44 $12.67

News

prnewswire.comKazia Therapeutics Appoints James Levine as Chief Financial Officerprnewswire.comJun 2

prnewswire.comKazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancerprnewswire.comMay 26

prnewswire.comKazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platformprnewswire.comApr 15

prnewswire.comKazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platformprnewswire.comApr 13

Trade KZIA

About Kazia Therapeutics Limited

Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.

CEO: John Edwin Friend
IPO Date: Jan 6, 1999

Market Data

Open: $14.63
High: $14.65
Low: $13.34
Volume: 195.8K
Avg Volume: 223.2K
52W High: $17.40
52W Low: $4.86

Valuation

Market Cap: $22M
Enterprise Value: $-37M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-13M
Revenue: $42k
Net Income: $-21M
Cash: $4.3M
Debt: $396k

Events

EarningsSep 4

EPS est. -0.69729